# US 5,914,113 A · Inactivated vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,914,113 A
- Document ID: US5914113A
- Status: Granted
- Kind: A
- Application number: 08/939,046
- Filed: 1997-09-26
- Granted: 1999-06-22
- Earliest claimed: 1996-09-27
- Assignees: Akzo Nobel N.V.
- Inventors: Carla Christina Schrier
- Web page: https://patentgrep.com/patent/US5914113A

## CPC

- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/12: Antivirals
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2720/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/12234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y10S 424/816: Viral vaccine for avian species, e.g. poultry or other birds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention is concerned with the preparation of improved inactivated vaccines, in particular of inactivated poultry vaccines. The immunogenicity of the inactivated immunogens in such vaccines is enhanced in case live CAV are administered in a combination vaccine with these inactivated immnogens.

## Claims

### Claim 1

A vaccine composition comprising one or more inactivated immunogens derived from avian pathogens, an adjuvant, and a live chicken anemia virus (CAV) immunogen.

### Claim 2 (depends on 1)

The vaccine composition according to claim 1, wherein the adjuvant is an oil-emulsion and the one or more inactivated immunogens are emulsified therein.

### Claim 3 (depends on 2)

The vaccine composition according to claim 2, wherein the adjuvant is a water-in-oil (w/o) emulsion.

### Claim 4 (depends on 3)

The vaccine composition according to claim 3, wherein the w/o emulsion constitutes a first phase and the live CAV immunogen constitutes a second phase of the vaccine composition.

### Claim 5 (depends on 4)

The vaccine composition according to claim 4, wherein the second phase comprises an aqueous solution of the live CAV immunogen.

### Claim 6 (depends on 2)

The vaccine composition according to claim 2, wherein the oil is a metabolizable oil.

### Claim 7 (depends on 3)

The vaccine according to claim 3, wherein the oil is a metabolizable oil.

### Claim 8 (depends on 4)

The vaccine according to claim 4, wherein the oil is a metabolizable oil.

### Claim 9 (depends on 5)

The vaccine according to claim 5, wherein the oil is a metabolizable oil.

### Claim 10 (depends on 1)

The vaccine composition according to claim 1, wherein the one or more inactivated immunogens are one or more killed whole microorganisms.

### Claim 11 (depends on 1)

The vaccine according to claim 1, wherein the one or more inactivated immunogens are inactivated whole viruses.

### Claim 12 (depends on 1)

The method of according to claim 1, wherein the live CAV immunogen is a live, attenuated CAV.

### Claim 13 (depends on 1)

A method of immunizing avian species against infectious diseases, comprising administering the vaccine of claim 1 to the birds.

### Claim 14 (depends on 13)

The method of claim 13, wherein the vaccine is administered parenterally.

### Claim 15 (depends on 1)

The vaccine composition according to claim 1, wherein the one or more inactivated immunogens of the avian pathogens are derived from poultry pathogens selected from the group consisting of Newcastle disease virus (NDV), Infectious bronchitis virus (IBV), Infectious bursal disease virus (IBDV), Turkey rhinotracheitis virus (TRTV), Infectious laryngotracheitis virus (ILTV), Egg drop syndrome (EDS) virus, avian encephalomyelitis virus, reticuloendotheleisis virus, avian pox viruses, avian adenoviruses, infectious coryza, fowl typhoid, fowl cholera, Mycoplasma gallisepticum. E. coli and Salmonella.

### Claim 16 (depends on 8)

The vaccine composition according to claim 8, wherein the inactivated immunogens of the avian pathogens are derived from poultry pathogens selected from the group consisting of IBV, NDV and IBDV.

### Claim 17

A vaccine kit for the protection of avian species against infectious diseases, comprising a first container comprising a live CAV immunogen and a second container comprising an oil-emulsion containing one or more inactivated immunogens derived from poultry pathogens.